In the nucleus, death receptors can function as tumor promoters and might be therapeutic targets. »
06/14/13

Histone modifications were not associated with recurrence-free or cancer-specific survival. »
07/15/13

Breast cancer risk remains low following CEE use among women having favorable baseline sex hormone profiles. »
03/26/14

Metabolic defects introduced by siRNA silencing of metabolic enzymes TKT or AK2 may be compensated by alternative feedback metabolic mechanisms. »
03/25/14

Selected lead compound GWARJD10 with EC50 10 μM against ROS production was shown to block AR-JunD interaction in situ. »
11/29/13

Chk2 depletion abrogated the cisplatin-induced S-phase cell cycle arrest and caused increased resistance to cisplatin in long-term clonogenic survival assays. »
01/23/14

microRNAs (miRNA) are emerging as important causal modulators in melanoma development and progression. »
03/17/14

Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC. »
03/28/14

Loss of PTK7 activated the MKK7-JNK stress response pathway and impaired tumor growth in xenotransplantation assays. »
03/22/14

Exposure to the anticonvulsant agent valproic acid, a histone deacetylase inhibitor, decreased solid tumor cancer risk. »
07/25/13